This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Receptor for advanced glycation endproducts (RAGE)	<i>In vitro</i> and mouse studies suggest antibodies against RAGE could help prevent cancer metastasis to the lungs. In mice injected with lung cancer or melanoma cell lines, pretreatment with an anti-RAGE antibody decreased tumor formation in the lungs compared with a control antibody pretreatment. Next steps include developing antibodies against the specific RAGE domains involved in mediating metastasis. Dynamis Therapeutics Inc.'s RAGE inhibitor, DYN-15, is in preclinical testing to treat diabetic retinopathy. SciBX 5(18); doi:10.1038/scibx.2012.465 Published online May 3, 2012	Unpatented; unavailable for licensing	Mizumoto, S. <i>et al. J. Biol. Chem.</i> ; published online April 9, 2012; doi:10.1074/jbc.M111.313437 Contact: Kazuyuki Sugahara, Hokkaido University, Hokkaido, Japan e-mail: k-sugar@sci.hokudai.ac.jp